BIOSIMILARS AND BIOLOGICAL MEDICATIONS: A NEW PHARMACEUTICAL APPROACH IN THE TREATMENT OF SEVERE AND CHRONIC DISEASES

Abstract

In the field of pharmacology, biologic drugs are revolutionary treatments for serious and chronic diseases such as cancer, rheumatoid arthritis, and autoimmune diseases. Produced from living organisms, they offer effectiveness and hope for patients unresponsive to conventional treatments. However, their high cost limits access. The article explores the importance of biologic drugs, highlighting their positive impact on health, but also the challenges, primarily related to cost. It introduces biosimilars, similar versions of already approved biologic drugs, which promise to make treatment more accessible. Bibliographic exploratory methodology is used to investigate the topic, identifying reliable sources. The results emphasize how biosimilars are becoming a viable alternative, regulated by agencies such as the FDA and EMA, which establish strict criteria. Biosimilars reduce costs and increase accessibility, relieving healthcare systems and enabling more patients to access vital treatments. They also encourage competition and price reduction. In conclusion, biosimilars are revolutionizing the pharmaceutical market, making state-of-the-art treatments more accessible. Despite the challenges, educating healthcare professionals and patients about their safety and efficacy is crucial. Biosimilars shape the future of serious disease treatment, balancing innovation and accessibility, with the potential to improve global healthcare.

 Keywords: Pharmacy. Biologic Drugs. Chronic biosimilars. Diseases.